BURLINGAME, Calif.– Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, will present positive topline data from the landmark spective study for ymtomatic relief of ssential tremor with ala herapy (PROSPECT) in a late-breaking poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders on September 25, 2019, in Nice, France. Cala Therapy, now marketed as Cala Trio, is available by prescription in the United States.
Cala Health Announces Positive Topline Data from Landmark PROSPECT Study for Essential Tremor
Posted on February 7, 2020
Categories: In the News